首頁 › 子宮內膜癌 › 明尼蘇達 › Minneapolis
Minneapolis, MN 的 子宮內膜癌 臨床試驗
18 項針對 子宮內膜癌 的研究正在 Minneapolis（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Abbott-Northwestern Hospital, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 距離 5 英里
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- Minnesota Oncology Hematology, PA ( Site 8003), Minneapolis
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
招募中3 期
- USOR - Minnesota Oncology/ Minneapolis Clinic, Minneapolis
- USOR - Minnesota Oncology, Minneapolis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
招募中1 期
- University of Minnesota Masonic Cancer Center, Minneapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- University of Minnesota, Minneapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
招募中3 期
- Research Site, Minneapolis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 518, Minneapolis
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
招募中1 期
- University of Minnesota, Minneapolis
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中觀察性研究歡迎健康志工
- Allina Health Cancer Institute, Minneapolis
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
招募中2/3 期
- Minnesota Oncology Hematology, P.A., Minneapolis
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Columbus, OH25 項研究
- Chicago, IL25 項研究
- Oklahoma City, OK25 項研究
Minneapolis 的其他研究
- 非小細胞肺癌27 項研究
- 乳癌27 項研究
- 卵巢癌24 項研究
- 前列腺癌23 項研究
- 癌症（所有類型）22 項研究
- 心臟衰竭21 項研究
- 急性髓系白血病20 項研究
- 肺癌20 項研究
- 大腸直腸癌19 項研究
- 帕金森氏症17 項研究
- 心血管疾病15 項研究
- 冠狀動脈疾病13 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。